Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11

DSpace/Manakin Repository

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11

Citable link to this page

 

 
Title: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
Author: Liao, Yunfei; Sassi, Slim; Halvorsen, Stefan; Feng, Yong; Shen, Jacson; Gao, Yan; Cote, Gregory; Choy, Edwin; Harmon, David; Mankin, Henry; Hornicek, Francis; Duan, Zhenfeng

Note: Order does not necessarily reflect citation order of authors.

Citation: Liao, Y., S. Sassi, S. Halvorsen, Y. Feng, J. Shen, Y. Gao, G. Cote, et al. 2017. “Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.” Scientific Reports 7 (1): 43941. doi:10.1038/srep43941. http://dx.doi.org/10.1038/srep43941.
Full Text & Related Files:
Abstract: Osteosarcoma is the most common bone cancer in children and adolescents. Previously, we have found that cyclin-dependent kinase 11 (CDK11) signaling was essential for osteosarcoma cell growth and survival. Subsequently, CDK11 siRNA gene targeting, expression profiling, and network reconstruction of differentially expressed genes were performed between CDK11 knock down and wild type osteosarcoma cells. Reconstructed network of the differentially expressed genes pointed to the AR as key to CDK11 signaling in osteosarcoma. CDK11 increased transcriptional activation of AR gene in osteosarcoma cell lines. AR protein was highly expressed in various osteosarcoma cell lines and patient tumor tissues. Tissue microarray analysis showed that the disease-free survival rate for patients with high-expression of AR was significantly shorter than for patients with low-expression of AR. In addition, AR gene expression knockdown via siRNA greatly inhibited cell growth and viability. Similar results were found in osteosarcoma cells treated with AR inhibitor. These findings suggest that CDK11 is involved in the regulation of AR pathway and AR can be a potential novel prognostic marker and therapeutic target for osteosarcoma treatment.
Published Version: doi:10.1038/srep43941
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338289/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071950
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters